Anteris Reports 2025 Financial Results and Provides Corporate Update
Anteris Technologies Global Corp. (AVR)
Company Research
Source: GlobeNewswire
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve patientsReceived FDA Investigational Device Exemption (“IDE”) approval in the fourth quarter of 2025 to initiate the PARADIGM Trial in the United StatesReported favorable 30-day (100 patients) and 1-year (65 patients) DurAVR® THV clinical outcomes from rolling cohorts of small annuli, symptomatic se
Show less
Read more
Impact Snapshot
Event Time:
AVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVR alerts
High impacting Anteris Technologies Global Corp. news events
Weekly update
A roundup of the hottest topics
AVR
News
- Anteris Technologies Global (AVR) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $15.00 price target on the stock.MarketBeat
- Anteris Technologies Global (AVR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $16.00 price target on the stock.MarketBeat
- Anteris Technologies Global (AVR) was upgraded by Cantor Fitzgerald to "strong-buy".MarketBeat
- Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Anteris to Present at Healthcare Investor Conferences TD Cowen and BarclaysGlobeNewswire
AVR
Sec Filings
- 3/10/26 - Form POS
- 3/6/26 - Form 4
- 3/3/26 - Form 8-K
- AVR's page on the SEC website